



Analysis of Clinically Actionable Preemptive Pharmacogenomic (PGx) Information to Impact In-Hospital Prescribing

Yee Ming Lee¹, PharmD,

Keith Danahey^{1,2} MS, Mark J. Ratain^{1,3,4}, MD, David O. Meltzer⁵, MD, PhD, Peter H. O'Donnell^{1,3,4}, MD

¹Center for Personalized Therapeutics, ²Center for Research Informatics, ³Committee on Clinical Pharmacology and Pharmacogenomics, ⁴Department of Medicine, ⁵Departments of Medicine and Economics, and Harris School of Public Policy, The University of Chicago, IL

BACKGROUND



- Traditional “one size fits all” vs Precision medicine
- Pharmacogenomics (PGx) goal: ↓adverse drug response, ↑drug efficacy
- Various institutions have begun implementing PGx ¹

3 issues on implementation

- a. Test approach: Reactive vs preemptive
- b. Standard for clinical actionable information: **CPIC**, **FDA**, DPWG
 - **CPIC: Clinical Pharmacogenetics Implementation Consortium**
 - **FDA: table of PGx biomarkers in drug labels**
 - DPWG: Dutch Pharmacogenetics Working Group
- c. Genotype population: Everyone vs high-risk groups²

HIGH STAKES SETTING



- At University of Chicago, 1200 Patients Project¹
 - Preemptively genotype patients seen by MD at outpatient clinic
 - Literature for clinically actionable pharmacogenes
 - Risk signals in **U of Chicago Genomic Prescribing System (GPS)**
- Stakes are high in the hospital
 - ~35 million hospital admissions per year in US ²
 - Average 45% of discharge medications newly started in hospital³
 - Acutely ill patients – at risk of adverse drug reactions (ADR)
 - ADR – 5.3% hospitalizations; higher rates in elderly⁴


HYPOTHESIS & AIM

- HYPOTHESIS: Clinically actionable preemptive PGx information made available in high volume and high stakes in-hospital setting, can significantly influence drug prescribing
- AIM: Pilot study to determine the potential opportunities for PGx information to influence drug prescribing



METHODS

- Retrospective analysis of outpatient genotyped cohort



Hospitalizations at
University of Chicago
Medical Center
2012 to 2015

Medication changes:
Compare admission
and discharge med list

Germline PGx information

- **CPIC-A list (35 drugs)**
- **FDA list (104 drugs)**
- **U Chicago GPS list (46 drugs)**


RESULTS: PATIENT DEMOGRAPHICS

CHARACTERISTICS – NO. (%)	OUTPATIENT GENOTYPED (N=867)	HOSPITALIZED (N=20)
Age (mean ± SD, years)	61.3 ± 15.5	78.2 ± 12.3*
Male	394 (45.4)	13 (65.0)
Caucasian	536 (58.8)	12 (60.0)
African-American	290 (31.8)	7 (35.0)
Asian	29 (3.2)	0 (0)
More than one race/other	27 (3.0)	0 (0)
Unknown	26 (2.9)	1 (5.0)
American Indian/Alaska native/ Pacific islander	4 (0.4)	0 (0)
No. of medications (mean ± SD)	5.0 ± 3.2	8.8 ± 3.9 *

* $P < 0.0001$

HOSPITALIZATION DETAILS

CHARACTERISTIC	HOSPITALIZED, N=20
Total no. of hospitalizations	38
Hospitalization rate per patient	1.9 (range 1 – 6)
Length of stay in hospital (days)	4.3 (range 0 – 22.6)
No. of baseline comorbidities (mean \pm SD)	7.4 \pm 4.8




MEDICATIONS WITH PGx INFORMATION

53% of the Hospitalizations involved PGx drug

Total 159 medications changed (74 distinct drugs)


- Per hospital visit: average 3.8 medications changed
 - 30% medications changed involved PGx drug



NEW MEDICATIONS WITH PGx INFORMATION

- Out of 74 distinct drugs changed, 66% were new
- 7 (14%) new medications had PGx info from at least one source

7 new PGx drugs affected 45% hospitalized patients



CONCLUSIONS



1. Majority of hospitalized patients undergo medication changes
2. Having PGx information from broad preemptive genotyping made available could significantly impact in-hospital prescribing
3. Preemptive genotype population: elderly, multiple medications

Future: Prospective study of broad preemptive PGx implementation among hospitalized patients

*Acknowledgements: Drs. Peter H. O'Donnell and Mark J. Ratain
The 1200 Patients Project team
The Committee on Clinical Pharmacology and Pharmacogenomics
The Center for Personalized Therapeutics
Support from The William O'Connor Foundation (MJR)*

